Cathie Wood: Multi-Omics Will Become the Most Profound Application of AI According to ARK Research
This application can help diagnose diseases before any physical symptoms appear, significantly reducing the cost and time of developing and delivering new drugs, and achieving disease cures, transforming "sickcare" into true healthcare.
Market mechanisms show that innovative capital is accelerating its flow into biotech companies that integrate multi-omics and AI, with funds selling off traditional drug development and late-stage treatment assets shifting towards early precision intervention fields. The event-driven nature is evident, benefiting companies that master multi-omics platforms and early diagnostic tool providers, while traditional pharmaceutical models that rely on post-symptom treatment are under pressure.
Source: Public Information
ABAB AI Insight
Cathie Wood and ARK Invest have previously heavily invested in precision medicine and gene technology companies, including early investments in CRISPR-related firms and data-driven medical platforms like Tempus. They have consistently increased their positions in biotech through the ARK Genomic Revolution ETF from 2021 to 2023, maintaining high exposure despite sector pullbacks.
The capital path indicates that ARK is shifting institutional and retail funds from general AI to vertically applied multi-omics, motivated by the goal of achieving exponential efficiency gains through the combination of data and AI, and strategically focusing resources on "platform + tools" for mergers and acquisitions.
Similar to how Illumina was initially dominant in gene sequencing before being replaced by new platforms, ARK is currently in an expansion phase of AI-driven biotech transitioning from research to clinical applications.
Essentially, this is a technological replacement, driven by the explosive growth of multi-omics data combined with breakthroughs in AI computing power, replacing traditional trial-and-error drug development processes, significantly compressing the time and capital waste from discovery to commercialization, and shifting pricing power towards data and algorithm owners.
ABAB News · Cognitive Law
Prevention is better than treatment, data precedes symptoms, AI leverages time upstream of diseases.
Cost is not the issue; the wrong path is; precision replaces trial and error, structure determines efficiency.
Selling drugs to treat existing diseases, the middle class buys AI concepts, top capital buys the future definition of health.